Exploring PRM-A as a novel glycan-targeted therapy for SARS-CoV-2 inhibition Post author: Post published:July 4, 2024 Post category:uncategorized HIV, Ebola and most recently, COVID-19 viruses have had an enormous impact on our societies world-wide. You Might Also Like Gut microbiota linked to fracture risk: Study reveals key microbial associations August 19, 2024 Inpatient costs of treating COVID-19 in the U.S. January 7, 2024 Nutrigenomics paves the way for customized diets in lactose intolerance care January 24, 2024